anmelden
SMI Expanded
1.812,08
PKT
-2,01
PKT
-0,11
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SMI Expanded-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.04.22 | Richemont Buy | Jefferies & Company Inc. | |
| 08.04.22 | Novartis Neutral | UBS AG | |
| 07.04.22 | Swiss Re Sell | Goldman Sachs Group Inc. | |
| 07.04.22 | Swiss Re Sell | UBS AG | |
| 07.04.22 | Swiss Re Hold | Jefferies & Company Inc. | |
| 07.04.22 | Swiss Re Neutral | JP Morgan Chase & Co. | |
| 07.04.22 | ams-OSRAM Hold | Deutsche Bank AG | |
| 06.04.22 | Nestlé Buy | UBS AG | |
| 06.04.22 | ams-OSRAM Neutral | UBS AG | |
| 06.04.22 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 06.04.22 | Nestlé Overweight | Barclays Capital | |
| 06.04.22 | ams-OSRAM Underweight | Barclays Capital | |
| 06.04.22 | ams-OSRAM Hold | Jefferies & Company Inc. | |
| 05.04.22 | UBS Outperform | RBC Capital Markets | |
| 05.04.22 | UBS Sector Perform | RBC Capital Markets | |
| 05.04.22 | ABB (Asea Brown Boveri) Buy | UBS AG | |
| 05.04.22 | ams-OSRAM Neutral | UBS AG | |
| 05.04.22 | Novartis Sell | Deutsche Bank AG | |
| 05.04.22 | Richemont Overweight | JP Morgan Chase & Co. | |
| 04.04.22 | Nestlé Overweight | JP Morgan Chase & Co. | |
| 04.04.22 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.04.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 04.04.22 | Richemont Buy | UBS AG | |
| 04.04.22 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
| 04.04.22 | ABB (Asea Brown Boveri) Hold | Jefferies & Company Inc. | |
| 01.04.22 | Novartis Underweight | JP Morgan Chase & Co. | |
| 01.04.22 | UBS Overweight | JP Morgan Chase & Co. | |
| 01.04.22 | UBS Underweight | JP Morgan Chase & Co. | |
| 01.04.22 | UBS Outperform | Credit Suisse Group | |
| 31.03.22 | DocMorris Sell | UBS AG | |
| 31.03.22 | Roche Buy | Deutsche Bank AG | |
| 31.03.22 | ams-OSRAM Overweight | JP Morgan Chase & Co. | |
| 31.03.22 | UBS Neutral | Goldman Sachs Group Inc. | |
| 31.03.22 | UBS Buy | Goldman Sachs Group Inc. | |
| 30.03.22 | Nestlé Neutral | Credit Suisse Group | |
| 30.03.22 | Roche Overweight | Barclays Capital | |
| 30.03.22 | Roche Buy | Merrill Lynch & Co., Inc. | |
| 30.03.22 | Roche Neutral | JP Morgan Chase & Co. | |
| 30.03.22 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.03.22 | Givaudan Neutral | Goldman Sachs Group Inc. |